Lung cancer (Amsterdam, Netherlands) · 2026
Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brosseau Solenn, Etienne Harry, Peoc'h Katell, Langlais Alexandra, Blanché Hélène, Foucher Pascal, Barlesi Fabrice, Domas Jean, Girard Philippe, Scherpereel Arnaud, Dumont Patrick, Derollez Marc, Quoix Elisabeth, Debieuvre Didier, Deleuze Jean-François, Leçon-Malas Véronique, Zalcman Gérard, Westeel Virginie, Mordant Pierre
Аннотация
INTRODUCTION: No specific follow-up strategy has shown to improve overall survival (OS) after surgical resection of non-small cell lung cancer (NSCLC). Club cell secretory protein (CCSP) is produced by bronchiolar club cells and shows promise as a survival biomarker as its concentration depends on degree of lung inflammation. Our objective was to evaluate prognostic impact of postoperative serum CCSP concentration on OS after resection of stage I to IIIA NSCLC in a post hoc ancillary analysis of the IFCT-0302 trial.
METHODS: Patients with at least 1 postoperative serum sample were included. The primary and secondary endpoints were OS and disease-free survival (DFS) as function of serum CCSP concentration.
RESULTS: The IFCT-0302 trial included 1775 patients. Among them, 946 patients (77% male, age 63.3 ± 9.3 years) with postoperative serum collection were divided into quartiles according to CCSP concentration: Q1 (CCSP < 4.72 ng/mL), Q2 (4.72 ≤ CCSP < 7.93 ng/mL), Q3 (7.93 ≤ CCSP < 13.73 ng/mL), Q4 (CCSP ≥ 13.73 ng/mL. Patients with CCSP ≥ 13.73 ng/mL had greater risk of death than patients with CCSP < 4.72 ng/mL according to univariable (HR 1.31 [95% CI 1.01-1.70]; p = 0.046) and multivariable analyses (HR 1.30 [95% CI 1.00-1.70]; p = 0.05). Patients with high CCSP experienced a greater risk of recurrence or death than patients with low CCSP according to univariable (HR 1.34 [95% CI 1.05-1.70], p = 0.017) and multivariable analyses (HR 1.32 [95% CI 1.04-1.68], p = 0.025]).
CONCLUSION: Post hoc analysis revealed that postoperative CCSP serum concentration was associated with OS and DFS in NSCLC resected patients. This finding provides insights for the development of personalized follow-up after surgical resection of NSCLC.
METHODS: Patients with at least 1 postoperative serum sample were included. The primary and secondary endpoints were OS and disease-free survival (DFS) as function of serum CCSP concentration.
RESULTS: The IFCT-0302 trial included 1775 patients. Among them, 946 patients (77% male, age 63.3 ± 9.3 years) with postoperative serum collection were divided into quartiles according to CCSP concentration: Q1 (CCSP < 4.72 ng/mL), Q2 (4.72 ≤ CCSP < 7.93 ng/mL), Q3 (7.93 ≤ CCSP < 13.73 ng/mL), Q4 (CCSP ≥ 13.73 ng/mL. Patients with CCSP ≥ 13.73 ng/mL had greater risk of death than patients with CCSP < 4.72 ng/mL according to univariable (HR 1.31 [95% CI 1.01-1.70]; p = 0.046) and multivariable analyses (HR 1.30 [95% CI 1.00-1.70]; p = 0.05). Patients with high CCSP experienced a greater risk of recurrence or death than patients with low CCSP according to univariable (HR 1.34 [95% CI 1.05-1.70], p = 0.017) and multivariable analyses (HR 1.32 [95% CI 1.04-1.68], p = 0.025]).
CONCLUSION: Post hoc analysis revealed that postoperative CCSP serum concentration was associated with OS and DFS in NSCLC resected patients. This finding provides insights for the development of personalized follow-up after surgical resection of NSCLC.